Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24065626 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Rohulla Vaseq und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Oncology, CIO Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cytokine-Induced Killer Cells, Lung Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Krebshilfe.
Abstract (Originalsprache)
Undeniably, immunotherapy has markedly improved the survival rate of cancer patients. The scenario is no different in lung cancer, where multiple treatment options are now available and the inclusion of immunotherapy yields better clinical benefits than previously used chemotherapeutic strategies. Of interest, cytokine-induced killer (CIK) cell immunotherapy has also taken a central role in clinical trials for the treatment of lung cancer. Herein, we describe the relative success of CIK cell therapy (alone and combined with dendritic cells as DC/CIKs) in lung cancer clinical trials and discuss its combination with known immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1). Additionally, we provide insights into the findings of several preclinical in vitro/in vivo studies linked to lung cancer. In our opinion, CIK cell therapy, which recently completed 30 years and has been approved in many countries, including Germany, offers tremendous potential for lung cancer. Foremost, when it is optimized on a patient-by-patient basis with special attention to the patient-specific genomic signature.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrated Oncology, CIO Bonn, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
- Department of Neurosurgery, University Hospital Bonn, 53127 Bonn, Germany.
ORCID-Profile: Rohulla Vaseq, Amit Sharma, Yutao Li, Ingo G H Schmidt-Wolf
Förderung
- Deutsche Krebshilfe
Zitieren
APA
Vaseq, R., Sharma, A., Li, Y., & Schmidt-Wolf, I. G. H. (2023). Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24065626
Vancouver
Vaseq R, Sharma A, Li Y, Schmidt-Wolf IGH. Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24065626
BibTeX
@article{Vaseq2023,
author = {Vaseq, Rohulla and Sharma, Amit and Li, Yutao and Schmidt-Wolf, Ingo G H},
title = {Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24065626}
}
EUVIMED